



	B.1	Alpha	Beta	Gamma	Delta	Zeta	Omicron
Name	hCoV-19/Switzerland/GE-SNRCI-29943121/2020	hCoV-19/Switzerland/2012212272/2020	hCoV-19/Switzerland/GE-33128281/2021	hCoV-19/Switzerland/GE-33115015/2021	hCoV-19/Switzerland/GE-33896105/2021	hCoV-19/Switzerland/GE-32966260/2021	hCoV-19/Switzerland/VD-HUG-36221084/2021
Gisaid accession ID	EPI_ISL_414019	EPI_ISL_2131446	EPI_ISL_981782	EPI_ISL_981707	EPI_ISL_1811202	EPI_ISL_897700	EPI_ISL_7605546
Clade	G	GRY	GH	GR	GK	G	GRA
Pango lineage	B.1	B.1.1.7	B.1.351	P.1	AY.122	P.2	BA.1


**Table S1.** Patient sample information from which virus isolates were obtained.




**Fig S1.** Domain organization and mutations of the SARS-CoV-2 Spike protein of different variants used in this study.




**Fig S2.** Escape of SARS-CoV-2 variants from preVOC elicited immunity. PRNT<sub>90</sub> titers against SARS-CoV-2 variants (B.1, Alpha, Beta, Gamma, Delta, Zeta and Omicron-BA.1) determined using convalescent pre-VOC plasma/sera. Source data are provided as a Source Data file.




**Fig S3.** Escape of SARS-CoV-2 variants from Alpha elicited immunity. PRNT90 titers against SARS-CoV-2 variants (Alpha, B.1, Beta, Gamma, Delta, Zeta and Omicron-BA.1) determined using convalescent Alpha sera. Source data are provided as a Source Data file.




**Fig S4.** Escape of SARS-CoV-2 variants from Beta elicited immunity. PRNT90 titers against SARS-CoV-2 variants (Beta, B.1, Alpha, Gamma, Delta, Zeta and Omicron-BA.1) determined using convalescent Beta sera. Source data are provided as a Source Data file.



**Fig S5.** Escape of SARS-CoV-2 variants from Gamma elicited immunity. PRNT90 titers against SARS-CoV-2 variants (Gamma, B.1, Alpha, Beta, Delta, Zeta and Omicron-BA.1) determined using convalescent Gamma sera. Source data are provided as a Source Data file.




**Fig S6.** Escape of SARS-CoV-2 variants from Delta elicited immunity. PRNT90 titers against SARS-CoV-2 variants (Delta, B.1, Alpha, Beta, Gamma, Zeta and Omicron-BA.1) determined using convalescent Delta sera. Source data are provided as a Source Data file.




**Fig S7.** Escape of SARS-CoV-2 variants from double-dose mRNA vaccination elicited immunity. PRNT90 titers against SARS-CoV-2 variants (B.1, Alpha, Beta, Gamma, Delta, Zeta and Omicron-BA.1) determined using sera/plasma from individuals with double-dose mRNA vaccination. Source data are provided as a Source Data file.










**Fig S8.** Escape of SARS-CoV-2 variants from prior SARS-CoV-2 infection followed by double-dose mRNA vaccination elicited immunity. PRNT90 titers against SARS-CoV-2 variants (B.1, Alpha, Beta, Gamma, Delta, Zeta and Omicron-BA.1) determined using plasma from individuals with prior SARS-CoV-2 infection followed by double-dose mRNA vaccination. Source data are provided as a Source Data file.



**Fig S9.** Escape of SARS-CoV-2 variants from Delta breakthrough infection elicited immunity. PRNT90 titers against SARS-CoV-2 variants (B.1, Delta and Omicron-BA.1) determined using sera from Delta breakthrough infection of double-vaccinated individuals. Source data are provided as a Source Data file.




**Fig S10.** Escape of SARS-CoV-2 variants from Omicron-BA.1 breakthrough infection elicited immunity. PRNT90 titers against SARS-CoV-2 variants (B.1, Delta and Omicron-BA.1) determined using sera from Omicron-BA.1 breakthrough infection of double and single vaccinated individuals. Source data are provided as a Source Data file.



**Fig S11.** Spearman correlation analysis between RBD-binding IgG titers and neutralizing titer (PRNT<sub>90</sub>) against 6 SARS-CoV-2 strains (B.1, Alpha, Beta, Gamma, Delta and Omicron-BA.1) from infection-derived convalescent samples. (A-D) Cohorts of convalescent specimens that are derived from individuals infected with (A) early-pandemic SARS-CoV-2 (pre-VOC), (B) Beta (C) Gamma (D) Delta. Asterisks indicate level of significance (two-sided), if no asterisks are shown, correlation is not significant, \*  $p$  value < 0.05, \*\*  $p$  value < 0.01, \*\*\*  $p$  value < 0.001, \*\*\*\*  $p$  value < 0.0001. Colors indicate Spearman's rho correlation coefficient. Source data are provided as a Source Data file.


A

mRNA vaccine, n= 16




B

mRNA vaccine + Delta infection, n= 13



C

mRNA vaccine + Omicron infection, n= 11



**Fig S12.** Spearman correlation analysis between RBD-binding IgG titer and neutralizing titer (PRNT<sub>90</sub>) against 6 SARS-CoV-2 strains (B.1, Alpha, Beta, Gamma, Delta and Omicron-BA.1) from post-vaccine and combined post-vaccine/infection-derived samples. (A-C) Cohorts consist of individuals with (A) double-dose mRNA vaccination, (B) Delta breakthrough infection of double-vaccinated individuals and (C) Omicron-BA.1 breakthrough infection following double (n=8) and single (n=3) mRNA vaccination. Asterisks indicate level of significance (two-sided), if no asterisks are shown, correlation is not significant, \*  $p$  value < 0.05, \*\*  $p$  value < 0.01, \*\*\*  $p$  value < 0.001, \*\*\*\*  $p$  value < 0.0001. Colors indicate Spearman's rho correlation coefficient. Source data are provided as a Source Data file.